Company intelligence / Profile preview

Japan BCG Laboratory

Bunkyo-ku, Tokyo, Japanbcg.gr.jp ↗

Ownership: Private
Employees: ~60
Development stage: Other

Overview

Japan BCG Laboratory has been the sole supplier of the Bacillus Calmette–Guérin (BCG) vaccine in Japan since 1952 and has distributed over 2.25 billion doses globally. Its vaccines are WHO-prequalified and used both for tuberculosis prevention and as an immunotherapy for bladder cancer. The company’s products are approved and commercially available in multiple countries[1][4][5].

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccineBiological products
Industry: Biotech

Drug pipeline

3 assets

BCG Japan

2 more assets in the full pipeline.

Request access →

Partnerships

UNICEFWorld Health Organization (WHO)Pan American Health Organization (PAHO)

Beyond the preview

Go deeper on Japan BCG Laboratory.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Japan BCG Laboratory.

Explore the full profile